Christine Veyrat‐Follet

Author

Also Known As

C VEYRATFOLLET, C Veyrat-Follet, C. VEYRAT-FOLLET, C. Veyrat-Follet, C. Veyrat‐Follet, Christine Veyrat-Follet, Christine Veyrat‐Follet, Veyrat-Follet, Christine

Publications

885

Citations

H-Index

Concepts

All Affiliations

Sanofi (France)Inserm Université Paris Cité Délégation Paris 7 Sorbonne Paris Cité

About

Christine Veyrat‐Follet is an author at Sanofi (France) specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	180
2	Biostatistics	2	2	66
3	Public Health	1	1	13
4	Epidemiology	1	1	13
5	Immunology	1	1	14

Christine Veyrat‐Follet

Publications

733

Citations

H-Index

Page 1

	Year	Citations
A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed‐effects models Hoai‐Thu Thai, France Mentré, Nicholas H. G. Holford, Pharmaceutical Statistics	2013	100
Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization Christine Veyrat‐Follet Clinical Pharmacology & Therapeutics	2000	77
International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents Michela Casanova, Enis Özyar, Catherine Patte, Cancer Chemotherapy and Pharmacology MedicinePharmacologyInduction TreatmentNasopharyngeal CarcinomaAnti-cancer Agent	2015	63
A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron Eugène Cox, Christine Veyrat‐Follet, Stuart L. Beal, Journal of Pharmacokinetics and Biopharmaceutics	1999	62
Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches Solène Desmée, France Mentré, Christine Veyrat‐Follet, The AAPS Journal UrologyMedicineBiostatisticsProstate-specific Antigen KineticsNonlinear Mixed-effect Models	2015	53
Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer Solène Desmée, France Mentré, Christine Veyrat‐Follet, BMC Medical Research Methodology	2017	47
Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors Cristiana Sessa, Patricia LoRusso, Anthony W. Tolcher, Clinical Cancer Research	2013	46
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically‐based pharmacokinetic modelling: application to docetaxel Hoai‐Thu Thai, Florent Mazuir, Sylvaine Cartot‐Cotton, British Journal of Clinical Pharmacology	2015	44
Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non‐ST‐segment elevation myocardial infarction René Bruno, P. Baille, Sylvie Retout, British Journal of Clinical Pharmacology	2003	43
Using the SAEM Algorithm for Mechanistic Joint Models Characterizing the Relationship Between Nonlinear PSA Kinetics and Survival in Prostate Cancer Patients Solène Desmée, France Mentré, Christine Veyrat‐Follet, Biometrics	2016	38

Page 1